Neopharm’s Q2 Net Loss Decreases
NeoPharm has reported a net loss of $1.9 million for the second quarter ended June 30, 2009, as compared to a net loss of $2 million for the
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).
SciClone and APR have entered into a licensing agreement granting SciClone the commercialization rights for APR’s anti-nausea drug – ondansetron RapidFilm for China and Vietnam. Ondansetron RapidFilm is